Your insurance approval does not automatically end on December 31. For GLP-1 prior authorization renewal—January or later—the starting point is your approval letter's expiration date. Prior authorization is the plan's advance decision about whether the medicine meets its medical-necessity rules. Approval does not guarantee payment. An existing prescription may need updated records for renewal, while a new plan may require a separate review.
November 20 leaves time to gather paperwork before December holidays. GLP-1 medicines act on a gut-hormone signal involved in appetite and blood sugar. Zepbound contains tirzepatide; Wegovy contains semaglutide.
GLP-1 prior authorization renewal January: three dates
Three dates help the prescriber's office work backward from the next refill:
| Date | Where it comes from | What it tells you |
|---|---|---|
| Authorization end date | Current approval letter or plan confirmation | When the current authorization ends |
| Next plan's effective date | Enrollment confirmation and benefit documents | When that plan's rules begin |
| Next refill date | Prescription and pharmacy records | When a delay could affect access |
The plan can confirm when it accepts renewal requests and whether an approval remains valid after January 1. A letter ending in March needs a different calendar from one ending in December. Neither date settles whether next year's benefit still covers the medicine.
HealthCare.gov defines preauthorization as a coverage review and cautions that it does not promise payment. The prescription, approval, covered-drug list, and pharmacy requirements still need to line up.
A December check can identify which office submits the renewal and how receipt is confirmed. A submission reference gives both offices something to track.
A Zepbound renewal concerns the branded prescription. Compounded tirzepatide is a separate pharmacy-prepared medication with its own prescription and payment arrangements. A brand authorization does not establish coverage for it.
What GLP-1 continuation authorization documents show
Continuation criteria are the plan's rules for paying for treatment already underway. They can differ from the rules for starting.
As of November 20, 2026, the day this article was written, one example is Cigna's Zepbound policy, marked “REVIEW DATE: 06/17/2026.” Its adult weight-management section allows eight months initially and one year for continuation when all requirements are met. Before eight months are complete, Cigna applies the initial criteria. For continuation, it requires at least 5% weight loss from before the person started any GLP-1 or dual GLP-1/GIP medicine, alongside the other criteria.
That policy uses BMI, a weight-to-height measure, from the same starting point. A lower BMI today does not automatically erase the original record. The member's own benefit documents take precedence; this example is not a universal rule.
The office's records may need to include:
- The current approval letter, reference number, and expiration date.
- The exact medicine and reason it was prescribed.
- Dated pretreatment height and weight, plus the current weight and visit notes.
- Treatment dates, prescribed dose, response, side effects, and any interruptions.
- Records of earlier treatments or ongoing weight-management support when the plan requests them.
A message saying “the medicine is helping” may leave a specific requirement unanswered. The useful packet matches each requirement to a dated record. The plan can also clarify which starting weight counts after a previous medication change.
Prior authorization renewal versus a new insurance plan
A new plan may use different continuation rules, even when the medicine and doctor stay the same. HealthCare.gov's prescription coverage guide points readers to the new plan's drug list, benefit summary, and coverage materials. The formulary is that covered-drug list.
Open enrollment GLP-1 coverage covers choosing a plan. For an already selected plan, the renewal question is whether it accepts the existing authorization and treatment history.
As of November 20, 2026, the day this article was written, Highmark has announced a renewal-related change for 2027. Its November 19 notice says Zepbound single-dose pens will lose preferred status under its Anti-Obesity Enhanced benefit starting January 1 and upon authorization renewal. It describes authorization for preferred alternatives through the existing approval's end date. The change applies to that Enhanced benefit; its Standard benefit is unaffected.
If the plan has removed the benefit, insurance dropping GLP-1 coverage explains that separate problem. Neither a renewed brand authorization nor a preferred-product change establishes reimbursement for compounded tirzepatide.
If the paperwork could leave a treatment gap
A possible interruption belongs in the conversation before the last covered refill. Coverage paperwork cannot decide a safe restart or justify changing treatment to meet an insurer's rule.
In SURMOUNT-4, published in JAMA in 2024, 670 adults without diabetes were assigned to continue tirzepatide or switch to placebo, an inactive comparison treatment. They had already received tirzepatide for 36 weeks. Over the next 52 weeks, average weight in the placebo group rose 14.0% from the weight at the switch. It fell another 5.5% with continued treatment.
The STEP 1 extension in Diabetes, Obesity and Metabolism in 2022 followed 327 participants after treatment ended. After semaglutide and the study's lifestyle program stopped, the semaglutide group regained about two-thirds of its previous weight loss over one year. These results describe long interruptions in study groups; they cannot predict one person's refill delay or outcomes with a compounded preparation.
As of November 20, 2026, the day this article was written, the Wegovy prescribing information, marked “Revised: 6/2026,” directs restarting gradual dose increases at a lower dose after two or more consecutive missed injections. The prescriber sets the actual restart plan. That brand-specific direction does not establish instructions for another prescription.
Where compounded tirzepatide fits
Tirzepatide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication. The U.S. Food and Drug Administration (FDA) does not review compounded drugs for safety, effectiveness, or quality before marketing. This is different from an FDA-approved product: the formulation offered here is not FDA-approved.
A licensed provider may still prescribe — that decision is between you and your doctor.
The plan can confirm whether it pays for the exact compounded prescription. Considering it is a separate clinical decision from renewing Zepbound coverage.
Before the prescriber's office closes for the holidays
A useful status check asks what the plan still needs, who is sending it, and how receipt will be confirmed. An incomplete request and a written denial require different responses. The guide to a denied GLP-1 prior authorization covers the appeal process.
The practical December handoff is a confirmed end date, the right records, and an agreed next contact. It gives the patient, office, and pharmacy a shared picture before January's refill.
At Promise, a licensed U.S. provider reviews every request and may prescribe or decline; not everyone qualifies.





